Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from KalVista Pharmaceuticals ( (KALV) ) is now available.
KalVista Pharmaceuticals has appointed Laurence Reid, Ph.D., to its Board of Directors, highlighting his extensive leadership experience in biotechnology. Dr. Reid’s addition is timely as KalVista progresses its novel treatment, sebetralstat, towards global market approval. This appointment comes amidst strategic efforts to transition the company into a commercial organization, aiming to bring transformative oral medicines for rare diseases to the market.
See more insights into KALV stock on TipRanks’ Stock Analysis page.